89
A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final, although suggestions for editorial changes are still welcome. Send your approval or comments to: John Walsh, PA, CDE at jwalsh@diabetesnet .com or by calling (619) 497-0900

A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Embed Size (px)

Citation preview

Page 1: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

A Patient Safety Initiative For Insulin Pumps

Manufacturing Standards to improve insulin pump use and medical outcomes

These proposals are near final, although suggestions for editorial changes are still welcome.

Send your approval or comments to: John Walsh, PA, CDE at [email protected] or by calling (619) 497-0900

Page 2: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Introduction

Over 500,000 insulin pumps are in use around the world, yet no formal guidelines regarding manufacturing standards and medical practice have been adopted by the diabetes clinical community and pump manufacturing industry.

These are suggestions for such standards and once approved will be incorporated into future insulin pumps or into current pumps where software changes allow.

These manufacturing standards are designed to Provide safer dosing increments to pump users Allow clinicians to make consistent dosing decisions when managing

a variety of pumps Allow adjunctive medical and accessory personnel (ER, surgical,

school nurses, etc.) to more easily be trained and interact with insulin pumps

Page 3: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Background Older insulin pumps were primarily designed to improve insulin

delivery. Technological advances have transformed today’s pumps and

controllers into data collection centers. As additional data from continuous glucose monitoring devices becomes more widely used, the value of this data becomes even greater.

Data needed for clinical monitoring and decisions is available in today’s pump and can be accessed through screen displays, alerts, or recommendations. Using routine monitoring techniques and data analyses, a pump can inform the wearer regarding their current control and changes in control.

Page 4: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

These Mechanical Standards Are Supported By:

John Walsh, PA, CDE Ruth Roberts, MA Gary Scheiner, MS, CDE Timothy Bailey, MD, FACE Steve Edelman, MD Carol Wysham, MD Joseph Largay, PA, CDE David Horwitz, MD Etc

* Reservations by a signatory about a standard will be noted

Page 5: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Definitions

TDD – total daily dose of insulin (all basals and boluses)

Basal –background insulin pumped slowly through the day to keep BG flat

Bolus – a quick surge of insulin as Carb boluses to cover carbs Correction boluses to lower high readings that arise from

too little basal insulin delivery or insufficient carb boluses

Bolus On Board (BOB) – the units of bolus insulin with glucose-lowering activity still working from recent boluses

Duration of Insulin Action (DIA) – time that a bolus will lower the BG. This is used to calculate BOB.

Page 6: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Why Insulin Pump Guidelines Are Needed

These mechanical standards are designed to improve:

1. Consistency of pump settings between pump manufacturers

2. Accuracy and safety of carb and correction factor increments

3. Safety and consistency of DIA defaults and increments

4. Consistency in the handling of BOB and insulin stacking

5. Improved monitoring for hypoglycemia & hyperglycemia

6. Improved entry of glucose values into bolus calculations

7. Faster notification of excessive use of correction boluses

8. Faster identification of control problems related to infusion sets

Page 7: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Overview

# Topic

1 Carb Factor Increments

2 Correction Factor Increments

3 Carb Factor Accuracy

4 Correction Factor Accuracy

5 DIA Default Times

6 DIA Time Increments

7 Handling Of BOB

# Topic

8. Multi-Linear And Curvilinear DIA

9. Hypoglycemia Alert

10. Hyperglycemia Alert

11. Correction Bolus Alert

12. Insulin Stacking Alert

13. Automatic Entry Of BG Values

14. Infusion Set Monitoring

Slides are numbered by topic for easy reference.

Page 8: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

ReviewWhat % of The TDD Changes The BG?

To understand some slides that follow, it helps to know the significance of the effect that a change in the TDD has on the glucose level.

Using a 450 Rule to set the carb factor and a 2000 Rule to set the correction factor: 1.25% of an appropriate TDD for an individual is sufficient to

change the glucose about 25 mg/dl when given as a single dose A 5% change in the TDD is equivalent to about a 25 mg/dl

increase or decrease in the glucose through the day A 5 to 6% change in the carb factor (about 2.5% to 3% of the

TDD) is sufficient to change the glucose about 20 mg/dl per meal.

Page 9: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Carb Factor Increments

1

Page 10: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Carb factor increments shall be less than or equal to 5% of the next larger whole number so that each single step adjustment causes subsequent carb boluses to change by no more than 5% from previous doses. We recommend minimum carb factor increments of: 5

1.0 g/u above 20 g/u

0.5 g/u for 10 to 20 g/u

0.2 g/u for 5 to 9.8 g/u

0.1 g/u for 3 to 4.9 g/u

0.05 g/u for 0.1 to 2.95 g/u

Standard For:Carb Factor Increments

1

5 Improved carb factor increments recommended by Gary Scheiner, MS, CDE

Page 11: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Issue: Current carb factor increments are too large to provide accurate carb boluses, especially for those who use smaller carb factors. This can represent a safety issue in situations where current carb factors lack the precision required to avoid excessive hyperglycemia and hypoglycemia.

1Carb Factor (CarbF) Increments

Page 12: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Most pumps offer 1 gram per unit as their smallest CarbF increment. This increment becomes relatively large for CarbFs below 15 or 20 g/u.

For instance, when the carb factor is reduced from 10 to 9 g/u, all subsequent carb boluses are increased by 11.1%. A shift in the carb factor from 1u/5g to 1u/4g causes each subsequent carb bolus to increase by 25%.

For most pump users, a change in the carb factor larger than 5 or 6% would be expected to create more than a 20 mg/dl shift in the glucose following each meal.

1ExampleCarb Factor Increments

Page 13: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

ExampleImpact On BG From CarbF Adjustments

This table shows the average additional fall in glucose after each meal of the day when a carb factor is reduced from 10 grams per unit to 9 grams per unit (for appropriate weight & TDD), and from 5 gr per unit to 4 gr per unit.

How A 1-Step Reduction In CarbF Impacts Avg. Postprandial BG

Change in CarbF

Weight

(~TDD)

Avg

Carb/dayAvg carb gms/meal

Change per meal

Change in BG per meal*

1/10 to 1/9160 lb

(~40 u)220 gr 73 gr

+ 1.47 u

(CorrF = 50)- 73.3 mg/dl**

1/5 to 1/4240 lb

(~100 u)330 gr 110 gr

+ 5.5 u

(CorrF = 20)- 110 mg/dl**

1

* Calculated as avg. carbs/day – avg. carbs/day X 1 X 2000 new carb factor old carb factor 3 TDD

** Meals with higher carb intake would magnify these sample glucose changes

Page 14: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

ReviewMedian Carb Factor

In unpublished data from the Cozmo Data Analysis Study: The median (middle) carb factor was 11.2 g/u

Almost all pumpers used carb factors below 20 g/u

40% or more use carb factors of 10 g/u.

1

Page 15: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

What Current Changes In CarbFs DoTable shows how subsequent carb boluses are affected by a one-step reduction in the CarbF using different CarbF increments. Yellow

area shows values for most current pumps. Green areas show safer increments that impact subsequent boluses less than 5%.

Orig. CF CF step 1 g/u CF step 0.5 g/u CF step 0.2 g/u CF step 0.1 g/u CF step 0.05 g/u20 5.26% 2.63% 1.05% 0.53% 0.26%19 5.56% 2.78% 1.11% 0.56% 0.28%18 5.88% 2.94% 1.18% 0.59% 0.29%17 6.25% 3.13% 1.25% 0.63% 0.31%16 6.67% 3.33% 1.33% 0.67% 0.33%15 7.14% 3.57% 1.43% 0.71% 0.36%14 7.69% 3.85% 1.54% 0.77% 0.38%13 8.33% 4.17% 1.67% 0.83% 0.42%12 9.09% 4.55% 1.82% 0.91% 0.45%11 10.00% 5.00% 2.00% 1.00% 0.50%10 11.11% 5.56% 2.22% 1.11% 0.56%9 12.50% 6.25% 2.50% 1.25% 0.63%8 14.29% 7.14% 2.86% 1.43% 0.71%7 16.67% 8.33% 3.33% 1.67% 0.83%6 20.00% 10.00% 4.00% 2.00% 1.00%5 25.00% 12.50% 5.00% 2.50% 1.25%4 33.33% 16.67% 6.67% 3.33% 1.67%3 50.00% 25.00% 10.00% 5.00% 2.50%2 100.00% 50.00% 20.00% 10.00% 5.00%

1

Page 16: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Correction Factor Increments

2

Page 17: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

For similar reasons, correction factor increments shall be less than or equal to 5% of the next larger whole number so that each single step adjustment causes subsequent correction boluses to change by no more than 5% from previous doses.

We recommend minimum correction factor increments of:

5.0 mg/dl per u above 80 mg/dl per u

2.0 mg/dl per u for 40 to 78 mg/dl per u

1.0 mg/dl per u for 20 to 39 mg/dl per u

0.5 mg/dl per u for 10 to 19.5 mg/dl per u

0.2 mg/dl per u for 5 to 9.8 mg/dl per u

0.1 mg/dl per u for 3 to 4.9 mg/dl per u

0.05 mg/dl per u for 0.1 to 2.95 mg/dl per u

Standard For:Correction Factor Increments

2

Page 18: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Carb Factor Accuracy

3

Page 19: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Standard For:Verification Of Carb Factor Accuracy

3

1. Insulin pump companies shall record and publish each year the carb factors used in insulin pumps returned for upgrade or repair. This report will include sufficient numbers of pumps to ensure statistical significance for commonly used carb factors between 5 and 20 grams per unit to ensure that pump training and clinical followup are assisting in the selection of accurate carb factors.

2. To improve accurate selection of carb factors, efforts shall be undertaken to automate carb factor testing.

Page 20: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Personal Carb Factors

Issue: Many carb factors used in insulin pumps today are poorly tuned to the user’s need.

When a carb factor does not match an individual’s need, other sources of error in carb bolus calculations are significantly magnified.

3

Page 21: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Review Carb Factors In Use 1

Avg. carb factors* for 468 consecutive Cozmo insulin pump downloads (>126,000 boluses) are shown in blue

Note that they are NOT bell-shaped or physiologic

People prefer “magic” numbers – 7, 10, 15, and 20 g/unit – for their carb factors

* Determined directly from grams of carb divided by carb bolus units for each carb bolus

7

10

115

20

J. Walsh, D. Wroblewski, and TS Bailey: Insulin Pump Settings – A Major Source For Insulin Dose Errors, Diabetes Technology Meeting 2007

1

3

Page 22: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

ReviewCarb Factors In Use 1

MANY magic carb factors, shown in blue, are inaccurate. A more normal or physiologic distribution is shown in green

Use of magic numbers creates major, consistent bolus errors that magnify other sources for error

7

10

115

20

J. Walsh, D. Wroblewski, and TS Bailey: Insulin Pump Settings – A Major Source For Insulin Dose Errors, Diabetes Technology Meeting 2007

1

3

Page 23: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Correction Factor Accuracy

4

Page 24: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Standard For:Verification Of Corr Factor Accuracy

4

1. Insulin pump companies shall record and publish each year the correction factors used in insulin pumps returned for upgrade or repair. This report will include sufficient numbers of pumps to ensure statistical significance for commonly used correction factors between 20 and 80 mg/dl per unit to ensure that pump training and clinical followup are assisting in the selection of accurate correction factors.

2. To improve accurate selection of correction factors, efforts shall be undertaken to automate correction factor testing.

Page 25: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Personal Correction Factors

Issue: Many correction factors used in insulin pumps today are poorly tuned to the user’s need. This inaccuracy significantly magnifies other sources of error in correction bolus calculations.

4

Page 26: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Review Correction Factors In Use 1

Avg. correction factors in use for 452 consecutive Cozmo insulin pump downloads

Like carb factors, correction factors in use are NOT bell-shaped or physiologic. A more accurate choice of correction factors would create a bell-shaped curve.

Users or clinicians appear to frequently select “magic” numbers for correction factors.

7

10

115

20

J. Walsh, D. Wroblewski, and TS Bailey: Insulin Pump Settings – A Major Source For Insulin Dose Errors, Diabetes Technology Meeting 2007

1

4

Page 27: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

DIA Default Times

5

Page 28: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Standard For:DIA Default Times

1. Default duration of insulin action (DIA) times in current pumps vary widely between 3 and 6 hours. For safety in bolus calculations that depend on DIA, the DIA default shall be set no shorter than 4.5 hours in pumps that determine DIA in a linear fashion and no shorter than 5 hours in pumps that determine DIA in a curvilinear or multi-linear fashion. These default times apply for the rapid insulins (lispro, aspart, and glulisine) in use at this time.

5

Page 29: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

DIA Default Time Settings

Issue: DIA measures the glucose-lowering activity of a carb or correction bolus over time. Current default times for DIA range from 3 to 6 hours in different pumps. The DIA is often considered another tool to “improve control”

rather than being set at an appropriate value and focusing on more appropriate changes in basal rates or carb and correction factors to improve control.

A DIA that is too short allows excess unrecognized bolus insulin to accumulate, usually in the afternoon and evening hours.

Example: a bolus given at 7 am appears to have no activity after 10 am. If a high BG occurs 10 am, more bolus than needed will be given. At lunch, the bolus will be excessive, regardless of the BG at that time, creating a high likelihood of hypoglycemia.

5

Page 30: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

ReviewHow Long Do Boluses Lower The BG?

Numerous GIR studies show rapid insulins lower the glucose for 5 hours or more.

With Novolog (aspart) at 0.2 u/kg (0.091 u/lb), 23% of glucose lowering activity remained after 4 hours.12

Another study found Novolog (0.2 u/kg) lowered the glucose for 5 hours and 43 min. +/- 1 hour.13

After 0.3 u/kg or 0.136 u/lb of Humalog (lispro), peak glucose-lowering activity was seen at 2.4 hours and 30% of activity remained after 4 hours. 11

These times would be longer if the unmeasured basal suppression in pharmacodynamic studies were accounted for.

11 From Table 1 in Humalog Mix50/50 product information, PA 6872AMP, Eli Lilly and Company, issued January 15, 2007.12 Mudaliar S, et al: Insulin aspart (B28 Asp-insulin): a fast-acting analog of human insulin. Diabetes Care 1999; 22:1501-1506.13 L Heinemann, et al: Time-action profile of the insulin analogue B28Asp. Diabetic Med 1996;13:683-684.

5

Page 31: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

A short DIA time hides true BOB level and its glucose-lowering activity. This can be a safety issue in that it: Leads to “unexplained” lows

Leads to incorrect adjustments in basal rates, carb factors, and correction factors

Causes users to start ignoring their “smart” pump’s advice

An inappropriately long DIA time overestimates bolus insulin activity – this leads to underdosing rather than overdosing on subsequent boluses.

DIA should be based on an insulin’s real action time.

Do NOT modify the DIA time to fix a control problem

ReviewShort DIAs Hide Bolus Insulin Activity

5

Page 32: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

ReviewDuration Of Insulin Action (DIA)

4 hrs 6 hrs2 hrs0

Glu

cose

-lowe

ring

Activ

ity

Accurate bolus estimates require an accurate DIA. DIA times shorter than 4.5 to 7 hrs may hide BOB and its glucose lowering activity

5

Page 33: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

ReviewDIA

Large doses (0.3 u/kg = 30 u for 220 lb. person) of “rapid” insulin in 18 non-diabetic, obese people

Med. doses (0.2 u/kg = 20 u for 220 lb. person)

This study suggests that residual insulin activity can lower glucose levels for 7-8 hours

Apidra product handout, Rev. April 2004a

Regular

5

Page 34: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

ReviewDoes Dose Size Affect DIA?

This graphic suggests that smaller boluses do not lower the BG as long as larger boluses.

However, this may not be true – see next 2 slides.

Size of the injected Humalog dose for a 154 lb or 70 kg person:

0.05 u/kg= 3.5 u

0.1 u/kg = 7 u

0.2 u/kg = 14 u

0.3 u/kg = 21 u

Woodworth et al. Diabetes. 1993;42(Suppl. 1):54A

5

Page 35: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

ReviewPharmacodynamics Is Not DIA

The DIA time entered into an insulin pump is based on studies of insulin pharmacodynamics.

However, the traditional method used to determine the pharmacodynamics of insulin may underestimate insulin’s true duration of action, as shown in the next two slides.

5

Page 36: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

ReviewPharmacodynamics Underestimates DIA And Overestimates Impact Of Bolus Size

To measure pharmaco-dynamics, glucose clamp studies are done in healthy individuals (0.05 to 0.3 u/kg)

Because there is no basal suppression, this injected insulin ALSO SUPPRESSES normal basal release from the pancreas (grey area in figure)

5

Page 37: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

ReviewPharmacodynamic Time Does Not Equal DIA

After accounting for the lack of basal suppression,

True DIA times become longer than the PD times derived in traditional research

If basal suppression activity is accounted for, small boluses may be found to have a longer DIA than it currently appears, erasingsome of the apparent variation in DIA related to bolus size

Some of the apparent inter-individual variation in pharmacodynamics may also disappear

5

Page 38: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

DIA Time Increments

6

Page 39: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

For safe and accurate estimates of residual BOB, DIA time increments shall be no greater than 15 minutes.

Standard For:DIA Time Increments

6

Page 40: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Issue: Current DIA time increments vary from 15 minutes to 1 hour in different pumps

When a pump’s DIA time is adjusted, large time increments, such as 1 hr, can introduce large changes in subsequent estimates of BOB.

For example, when the DIA is reduced from 5 hours to 4 hours, subsequent BOB estimates are decreased and recommendations for carb boluses are increased by about 25%.

6DIA Time Increments

Page 41: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Most GIR studies suggest that pharmacodynamic action of insulin varies only about 25% to 40% between individuals.

For a DIA time of 5 hr and 15 min, a 25% range is equivalent to 1 hr and 20 min, such as from 4 hrs and 30 min to 5hr and 50 min.

A pump that has 1 hr DIA increments would enable the user to select only 1 or 2 settings within this physiologic range, while a 30 min increment would allow only 2 or 3 choices that are close to a physiologic range.

6ReviewGlucose Infusion Rate (GIR) Studies

Page 42: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Handling Of BOB

Bolus On Board (BOB)

7

Page 43: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Standard For:Handling Of BOBFor safe and accurate BOB measurement:

BOB measurements shall include all carb and correction boluses given within the selected DIA When residual BOB is present at the time of a bolus, the BOB shall be subtracted from both carb and correction bolus recommendations. When BOB exceeds the current correction bolus need or the current carb plus correction need, the user will be alerted to how many grams of carb they need to eat.[(BOB – correction & carb bolus need) X carb factor]

7

Page 44: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Issue: Current pumps differ significantly in what is counted as BOB and in whether or not BOB is subtracted from subsequent carb boluses.

Most insulin pumps assume that excess BOB does not need to be taken into account when determining the next carb bolus.

Though commonly determined in this way, the resulting bolus dose recommendations can cause unexplained and unnecessary insulin stacking and hypoglycemia.

Handling Of BOB7

Page 45: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

ExampleInsulin Stacking

With a bedtime BG of 173 mg/dl,

is there an insulin deficit or a carb deficit?

6 pm 8 pm 10 pm 12 am

DinnerDinner

DessertDessertCorrectionCorrection Bedtime BG

= 173 mg/dl

7

Page 46: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

ReviewFrequency Of Insulin Stacking

CDA1 Study ResultsOf 201,538 boluses, 64.8% were

given within 4.5 hrs of a previous bolus

Although 4.5 hours may underestimate true DIA, use of this minimal DIA time shows that some BOB is present for MOST boluses

4.5 hrs

J. Walsh, D. Wroblewski, and TS Bailey: Disparate Bolus Recommendations In Insulin Pump Therapy. AACE Meeting 2007

7

Page 47: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

ReviewBolus On Board (BOB)

An accurate measurement of the glucose-lowering activity that remains from recent boluses:

• Prevents insulin stacking

• Improves bolus accuracy

• Allows the current carb or insulin deficit to be determined

aka: insulin on board, active insulin, unused insulin** Introduced as Unused Insulin in 1st ed of Pumping Insulin (1989)

7

Page 48: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

ReviewHow Current Pumps Handle BOB

What’s In the BOB & What Is It Applied Against?

BOB Includes This Type Of Bolus

BOB Is Subtracted From This Type Of Bolus

Carb Correction Carb Correction

Animas 2020 Yes Yes No* Yes

Deltec Cozmo Yes Yes Yes Yes

Insulet Omnipod No Yes No Yes

Medtronic Paradigm Yes Yes NoYes

* Except when BG is below target BG

* “Yes” is generally safer

7

Page 49: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

ExampleUnsafe BOB1 Handling

If a pump user gets frustrated with a high BG and they overdose to speed its fall, or they exercise longer or more intensely than anticipated, they can acquire a significant excess in BOB.

In this situation, most current pumps recommend that a bolus be given for all carb intake regardless of how much BOB is actually present.

If BOB is greater than the correction bolus requirement at the time, the pump’s bolus recommendation may introduce a risk for hypoglycemia.

1 Pumping Insulin, 1st ed, 1989, Chap 12, pgs 70-73: The Unused Insulin Rule

7

Page 50: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

ExampleDifferences In Bolus Recommendations

Situation: BOB = 3.0 u and 30

gr. of carb will be

eaten at these glucose

levels

Carb factor = 1u / 10 gr

Corr. Factor = 1 u / 40 mg/dl over 100

Target BG = 100

TDD = ~50 u

0

1

2

3

4

60 90 120 150 180 210 240

Deltec Cozmo Animas 1250 Medtronic 522

units

mg/dl

Omnipod bolus cannot be determined - it counts only correction bolus insulin as BOB

The graphic shows how widely bolus recommendations vary from one pump to another for the same situation.

7

Page 51: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

ReviewTrack BOB Or Carb Digestion?

For safety after meal and correction boluses, tracking the glucose-lowering action of BOB is more important than accounting for the glucose-raising action of digesting meal carbs: When a BG is taken after a meal, the BOB times the correction factor

ideally represents the maximum fall in glucose expected.

Accounting for the impact of the BOB on the current glucose provides the safest approach in the determination of bolus recommendations.

Low glycemic index meals, gastroparesis, Symlin, and other issues may counteract a predicted fall in glucose based on BOB, but the user can more easily judge and remedy this situation than dealing with an unknown excess of insulin.

7

Page 52: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Exceptions To Usual Handling Of BOB

When a second bolus is taken for an unplanned carb intake or a desert that is consumed within 60 minutes* or so of a meal bolus, BOB should not be taken into account for the second bolus because the impact of the first bolus cannot be accurately determined.

Given that, it is wise to account for BOB as soon after a meal as possible, such as within 60 to 90 minutes,* to provide early warning if the bolus given was excessive or inadequate.

Accounting for all BOB and applying it to subsequent boluses is generally safer, although not always more accurate.

7

* Adjustable setting in pump/controller

Page 53: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Multi-Linear And Curvilinear DIA

8

Page 54: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Standard For:Multi-Linear And Curvilinear DIA

Insulin pumps shall use either a 100% curvilinear or a multi-linear method to improve accuracy and consistency of BOB estimates.

8

Page 55: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Linear And Curvilinear DIA

Issue: Pump manufacturers use at least 3 different methods (100% curvilinear, 95% of curvilinear, and straight linear) to measure DIA and BOB.

When a realistic DIA time is selected, a linear determination of residual BOB will not be as accurate as a curvilinear method that incorporates the slow onset of insulin action and its longer tailing off in activity. In most situations, an accurate determination of insulin’s tailing activity will be most important to the pump user.

8

Page 56: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Linear And Curvilinear DIA Compared

Note how values for the 5 hr linear line in red and the thinner 5 hr curvilinear line diverge in value at several points along the graph.

5 hr Linear

5 hr 95% Curvilinear

From Pumping Insulin, 4th ed., adapted fom Mudaliar et al: Diabetes Care, 22: 1501, 1999

8

Page 57: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

ExampleA Multi-Linear DIA

Use of a multi-linear method to measure DIA improves accuracy. The next page shows a triple-linear example for measurement of BOB.

8

Page 58: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

ExampleA Triple-Linear Approximation Of DIA

A triple-linear line in red can more closely approximate a curvilinear DIA.

For a 5 hr DIA*:

1st 10%** – no change

Mid 65%** – fall 75%**

Last 25%** – fall 25%** (** adjustable as needed in device)

5 hr Triple Linear

8

* % modification suggested by Gary Scheiner, MS, CDE

Page 59: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Hypoglycemia Alert

9

Page 60: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Standards For:Hypoglycemia Alert

1. Insulin pumps that store glucose and insulin dosing data shall present this glucose control data in a readily accessible form on the pump or controller.

2. The pump shall alert the user when the glucose data from their glucose monitor or continuous monitor suggests they are experiencing frequent* or severe* patterns of hypoglycemia.

9

* Adjustable settings in pump/controller

Page 61: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Frequent/Severe Hypoglycemia Alert

Issue: Although most current insulin pumps contain sufficient data to do so, pumps give no warning to a user when they are experiencing patterns of frequent or severe hypoglycemia.

9

Page 62: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

ExamplePump Screen Hypoglycemia Display 1

9

* Adjustable settings in pump/controller

Weekly History – Low BGs

# of weeks 1 2 4 8

# BGs/week 23 25 28 32

% BGs/week < 50 mg/dl*

22% 18% 11% 8%

% BGs/week < 70 mg/dl*

35% 27% 19% 16%

Modified to % display per Gary Scheiner, MS, CDE

Page 63: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

ExamplePump Screen Hypoglycemia Display 2

9

* Adjustable settings in pump/controller

Low BGs By Time Of Day For 1 Week*

Avg BGs for 1 week 23 (3.3/day)

Time Period 4a-10a 10a-4p 4a-10p 10p-4a

% BGs < 50 mg/dl* 57% 14% 0% 0%

% BGs/week < 70 mg/dl* 71% 28% 0% 14%

Modified to % display per Gary Scheiner, MS, CDE

Page 64: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Hyperglycemia Alert

10

Page 65: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Standards For:Hyperglycemia Alert

1. Insulin pumps that store glucose and insulin dosing data shall present this glucose control data in a readily accessible form on the pump or controller.

2. The pump shall alert the user when the glucose data from their glucose monitor or continuous monitor suggests they are experiencing patterns of frequent* or severe* hyperglycemia.

10

* Adjustable settings in pump/controller

Page 66: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Frequent/Severe Hyperglycemia

Issue: Although most current insulin pumps contain sufficient data to do so, pumps give no warning to a user when they are experiencing patterns of frequent or severe hyperglycemia.

10

Page 67: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

ExamplePump Screen Hyperglycemia Display 1

10

* Adjustable settings in pump/controller

Weekly History – High BGs

# of weeks 1 2 4 8

Avg BGs/week 23 25 28 32

% BGs/week > 180 mg/dl*

26% 30% 29% 26%

% BGs/week >220 mg/dl*

17% 18% 22% 23%

Modified to % display per Gary Scheiner, MS, CDE

Page 68: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

ExamplePump Screen Hypoglycemia Display 2

10

* Adjustable settings in pump/controller

Low BGs By Time Of Day For 4 Weeks*

# BGs for 4 weeks 112 (4.0/day)

Time Period 4a-10a 10a-4p 4a-10p 10p-4a

% BGs > 180 mg/dl* 1% 3% 4% 21%

% BGs/week > 220 mg/dl* 0% 2% 3% 18%

Modified to % display per Gary Scheiner, MS, CDE

Page 69: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Correction Bolus Alert

11

Page 70: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Standard For:Correction Bolus Alert1. Insulin pumps shall show in a readily accessible history

screen the percentage of the TDD that is used for correction boluses over time.

2. The insulin pump shall alert the wearer when they are using more than 8%* of their TDD for correction bolus doses in the most recent 4 day* period.

11

* Adjustable settings in pump/controller

Page 71: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Correction Bolus Alert

Issue: Hyperglycemia is more common than hypoglycemia for most people on insulin pumps.

When glucose levels consistently run high, many pump users address the problem by giving frequent correction boluses rather than correcting the core problem through an increase in their basal rates or carb boluses.

If the correction bolus % becomes excessive relative to the TDD, this information is often not shown and no alert is given regarding the possible excessive use of correction boluses.

11

Page 72: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Insulin Stacking Alert

Accurate accounting of BOB becomes more important in those who experience frequent or severe hypoglycemia, as well as those whose average glucose levels are closer to normal values.

12

Page 73: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Standard For:Insulin Stacking Alert

Insulin pumps shall alert the wearer when they are giving a bolus and no glucose value has been entered in the pump. This is especially necessary when the user has sufficient insulin stacking* to significantly alter the bolus they would otherwise give.

The alert is on by default once a DIA time is selected to measure BOB, but may be turned off if the user desires.

* Such as when the BOB is greater than 1.25%** of the avg. TDD, sufficient to change the glucose about 25 mg/dl. (** Adjustable setting in pump/controller for a certain fall in glucose selected by the user or clinician)

12

Page 74: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Insulin Stacking Alert

Issue: Pump users often bolus for carbs without checking their glucose first. With no glucose reading, the pump cannot account for BOB, nor appropriately adjust a bolus for the BOB or the current BG.

Even without a glucose test, data available in the pump at the time of a bolus can determine whether enough BOB is present to substantially change a bolus dose. The pump can alert the user to this unseen, substantial insulin stacking.

12

Page 75: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

When a carb bolus is planned without a recent BG check, but BOB is more than 1.25%* of the average TDD (enough to cause about a 25 mg/dl drop in the glucose), the pump will recommend that the wearer do a BG check due to the substantial presence of BOB.

For instance, for someone with:

Avg TDD 1.25%* of TDD

40 units 0.5 units

50 mg/dl per u (corr factor) X 0.5 u = 25 mg/dl

This individual would be alerted when they do not check their glucose and want to give a bolus but have 0.5 u or more of BOB present.

ExampleInsulin Stacking or BOB Alert

* Adjustable in pump/controller for a reasonable degree of safety

12

Page 76: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Automatic Entry Of BG Values

13

Page 77: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Standard For:Automatic Entry Of BG Values

For completion of the glucose history, improved handling of BOB, and more accurate bolus recommendations, insulin pumps shall be enabled to have wireless or direct entry of BG test results from a glucose meter.

Automatic glucose entry from two or more major brands of meters is recommended to increase the likelihood of insurance coverage for test strips.

13

Page 78: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Automatic Entry Of BG Values

Issue: Pump users do not enter as many BG values into their pump when readings must be entered manually rather than having a glucose value automatically entered from a meter.

When a glucose is checked but not entered, the lost data cannot be used to account for BOB, warn of insulin stacking (see #12), nor be used to analyze glucose patterns and the frequency of hypoglycemia and hyperglycemia.

Relatively normal and hypoglycemia values are less likely to be entered manually, but are more likely to be influenced by BOB.

13

Page 79: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

ReviewAutomatic Entry Of BG Values

In a study of over 500 insulin pumps where BG values could be entered either manually or automatically, users entered 2.6 BG values per day manually, compared to 4.1 values per day for pumps in which glucose values wre automatically entered. *

BOB could typically be taken into account for 1.5 additional boluses per day with automatic entry of BG values.

When glucose values are not automatically entered, BOB cannot be determined and bolus recommendations will not be as accurate.

13

* J. Walsh, D. Wroblewski, T.S. Bailey: unpublished data

Page 80: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

ReviewAutomatic Entry Of BG Values

Automatic entry of glucose values into pumps offers a significant clinical advantage to users because more boluses will be adjusted for high and low BGs, and residual BOB is more likely to taken into accout in bolus calculations.

Automatic entry of glucose values ensures a greater degree of safety for those who experience frequent or sever hypoglycemia, and those whose glucose values are closer to normal.

13

Page 81: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Infusion Set Monitoring

14

Page 82: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Standards For:Infusion Sets

1. Insulin pumps shall monitor and record in easily accessible history the duration of infusion set usage recorded as mean, median, and SD of time of use.

2. Insulin pumps shall monitor and report average glucose values in full and partial 24 hour* time intervals between set changes with the ability to change the observation interval, such as 1 to 30 set changes.*

3. These steps allow the HCP and user to identify infusion set problem from loss of glucose control and variations in patterns of use.

14

* Adjustable setting in pump/controller

Page 83: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Infusion Sets

Issue: A significant number of non-patch pump wearers encounter infusion set problems. These problems may arise from poor infusion set design or inadequate site preparation. Often the source for the randomly erratic glucose readings that follow are difficult to identify by a user or clinician.

14

Page 84: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

ReviewInfusion Set Failure

One common problem source for infusion set failure arises when a Teflon infusion set comes loose beneath the skin from movement or tugging. Some of the infused insulin then leaks back to the skin surface resulting in unexplained high readings.

A complete loss of glucose control is typically seen when an infusion set is pulled out entirely.

Selecting the right infusion set plus good site technique, especially taping the infusion line to the skin, can significantly minimize the number of unexplained high readings for many pump wearers.

14

Page 85: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Why The Tubing Needs To Be Taped

Most problems with infusion sets come from loosening of the Teflon under the skin, not from a complete pullout. A 1” tape placed on the infusion line:

Stops tugging on the Teflon catheter under the skin

Prevents loosening of the Teflon catheter under the skin

Avoids many “unexplained highs” caused when insulin leaks back to the skin surface

Reduces skin irritation

And prevents many pull outs

14

Page 86: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Tape The Tubing

This helps prevent

Tugging

Irritation

Bleeding

14

Page 87: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

No tape!

14ExamplesLack Of Anchoring Of Sets

A review of dozens of pictures of infusion sets online and pump manuals finds that anchoring of the infusion line with tape is rarely recommended or practiced.

Page 88: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

Review Infusion Set Monitor

Many pump wearers experience random erratic readings until they change to a different infusion set or start to anchor their infusion lines with tape to stop line tugging.

However, insulin pumps offer no mechanism for clinicians or pump users to detect who may be having problems with their infusion sets.

14

Page 89: A Patient Safety Initiative For Insulin Pumps Manufacturing Standards to improve insulin pump use and medical outcomes These proposals are near final,

ToolInfusion Set Monitor

Insulin pumps with direct BG entry can identify those who may be having intermittent loss of glucose control secondary to infusion set failure. The pump: Shows the average time and variation in time of use

between reservoir loads or use of the priming function.

Shows average BGs for each full or partial 24* hour time interval following set changes (indicated by the prime function) over a various number of set changes* or as soon as statistical significance is reached.

14

* Adjustable setting in pump/controller